Tenax Therapeutics financials
$1.84−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$18.8M | -$16.6M | -$16.4M | -$16.8M | -$11.8M | -$11.3M | -$7.3M | -$4.6M | -$3.7M | -$3.9M | -$3.3M | -$2.1M |
| Net income | -$17.8M | -$15.7M | -$15.5M | -$15.8M | -$10.8M | -$10.4M | -$6.3M | -$4.0M | -$3.6M | -$3.8M | -$3.2M | -$2.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.35 | $-0.35 | $-0.38 | $-0.40 | $-0.27 | $-0.28 | $-0.17 | $-0.19 | $-1.83 | $-3.12 | $-10.65 | $-6.61 |
| EBITDA | -$18.8M | -$16.6M | -$16.4M | -$16.8M | -$11.8M | -$11.3M | -$7.3M | -$4.6M | -$3.7M | -$3.9M | -$3.3M | -$2.1M |
| Operating cash flow | -$14.2M | -$9.3M | -$13.4M | -$9.2M | -$6.3M | -$7.0M | -$3.5M | -$3.1M | -$3.0M | -$5.2M | -$1.2M | -$2.1M |
| Free cash flow | -$14.2M | -$9.3M | -$13.4M | -$9.2M | -$6.3M | -$7.0M | -$3.5M | -$3.1M | -$3.0M | -$5.2M | -$1.2M | -$2.1M |
| Diluted shares | 50.9M | 45.2M | 41.0M | 39.7M | 39.6M | 36.6M | 36.7M | 21.2M | 2.0M | 1.2M | 0.3M | 0.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $118.0M | $118.8M | $97.6M | $99.4M | $105.5M | $111.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $121.7M | $123.2M | $104.2M | $102.8M | $105.9M | $112.1M |
| Total liabilities | $8.1M | $8.5M | $7.2M | $6.6M | $2.5M | $2.8M |
| Shareholders' equity | $113.6M | $114.7M | $97.1M | $96.2M | $103.3M | $109.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology